- Animal studies and experiments involving cells cultured in the laboratory suggest that the Omicron variant may have a reduced ability to infect the lungs, compared with the Delta variant.
- This could explain why the Omicron variant appears to cause less severe disease than the Delta variant.
- These studies indicate that the Omicron variant could be more efficient at infecting the upper airways than the Delta variant, potentially explaining its increased contagiousness.
- The ability of the Omicron variant to escape neutralizing antibodies may also be responsible for its increased transmissibility.
All data and statistics are based on publicly available data at the time of publication. Some information may be out of date. Visit our coronavirus hub for the most recent information on the COVID-19 pandemic.
Sequencing of the Omicron genome suggested that this variant carries a large number of mutations, including on the spike protein. The large number of mutations carried by Omicron could be a potential reason for this reduction in illness severity.
However, the milder disease due to an Omicron infection could also be a result of a person’s enhanced immunity, acquired due to vaccination or past SARS-CoV-2 infections.
Although an increase in immunity may influence the severity of illness, studies in animals and cells cultured in the laboratory suggest that the mutations carried by the Omicron variant have made it less efficient at infecting the lungs than the Delta variant. This could explain the less severe illness that the Omicron variant causes.
The SARS-CoV-2 virus can affect both the upper and lower respiratory tracts. The upper respiratory tract consists of the nose, sinuses, and throat, whereas the lower respiratory tract includes the trachea and the lungs.
Severe illness due to the wild-type SARS-CoV-2 and the previous variants
Inflammation can cause fluid to accumulate in the air sacs, or alveoli, in the lungs, reducing the capacity of the lungs to transfer oxygen to the blood.
Scientists have conducted experiments using animal models and laboratory cultures of lung cells to characterize the ability of Omicron to infect the respiratory tract and cause severe illness.
This includes a study carried out at the University of Hong Kong that used human lung cells cultured in the laboratory, to analyze the ability of the Omicron variant to infect the lungs. These cells were cultured from lung tissue removed during treatment of the lung. Typically, this tissue is discarded.
In the study, Omicron replicated 70 times faster than Delta in the human bronchi, which are the tubes connecting the trachea with the lungs. However, it was less efficient at replicating in the lung tissue than Delta and the wild-type SARS-CoV-2.
There is a link between infection with the Delta and other variants and weight loss in hamsters and mice after 1 week, with some data suggesting a correlation between increased virus levels in the respiratory tract and weight loss.
However, various research groups have independently shown an
Moreover, these studies found that the hamsters with an Omicron infection showed higher or similar levels of virus, compared with the wild-type SARS-CoV-2 and the Delta variant in the upper respiratory tract. By contrast, the researchers observed lower levels of the virus in the lower respiratory tract after infection with the Omicron variant, compared with the Delta variant.
In sum, these studies show that Omicron may be less efficient at infecting the lungs. Significantly, these animal studies show that an Omicron infection results in lower levels of inflammation and injury to the lungs.
Consistent with this, there is growing evidence suggesting that people with an Omicron infection are less likely to be hospitalized or to require intensive care unit admission or mechanical ventilation than individuals with the Delta variant.
Medical News Today spoke with Dr. Scott Roberts, a professor of infectious diseases at the Yale School of Medicine in New Haven, CT. He said,
“A number of laboratory-based studies have now shown that the Omicron variant is less able to infect the lungs as well as other variants and, as a result, is leading to less patients being admitted with pneumonia who require oxygen and ventilators.”
“We are seeing [that] the majority of patients infected with Omicron have mild disease that is more localized to the upper respiratory tract and that hospitalizations are not rising as fast as they have with prior variants,” Dr. Roberts added.
“However, hospitalizations and deaths lag behind overall case counts, and as our cases are continuing to rise and set daily records, we ultimately need to wait several more weeks to get a full picture of disease severity here, in the United States.”
A potential reason for the less severe infection of the lower respiratory tract by Omicron in the present studies could be the changes in the ability of this variant to enter cells in the lower respiratory tract.
The Omicron variant carries a large number of
The SARS-CoV-2 spike protein binds to the ACE2 receptor expressed on lung cells and helps the virus enter the cell. The cleavage of the spike protein by an enzyme called
The SARS-CoV-2 virus can also enter human cells by an alternative pathway. This pathway involves the engulfment of the virus by endosomes, which are membrane-bound sacs present inside the cell.
These studies have found that the Omicron variant is less effective at infecting laboratory-cultured lung cells expressing TMPRSS2 than the Delta variant.
By contrast, Omicron is more effective than Delta at infecting cells that allow cell entry through the endosome pathway.
The ACE2 receptor and TMPRSS2 are expressed at higher levels in cells obtained from the lower respiratory tract of humans than in cells from the upper respiratory tract. This could potentially explain why the Omicron variant may be less effective at infecting the lower respiratory tract and causing severe disease.
The interaction of the SARS-CoV-2 spike protein and TMPRSS2 is also involved in mediating the fusion of infected human cells with adjacent uninfected cells.
The reduced ability of the Omicron spike protein to utilize the TMPRSS2 enzyme also limits its ability to infect adjacent cells. This could further contribute to the lower severity of lower respiratory tract infection due to COVID-19.
These results are from cell culture and animal studies. Therefore, human studies are necessary to establish that such a change in Omicron is responsible for its reduced ability to infect lung cells.
MNT spoke with Dr. Peter Kasson, a professor at the University of Virginia in Charlottesville. He said:
“The Omicron variant is interesting in that it appears to swap preferences for entry pathway compared to Delta and prior variants. As a result, it is less efficient at infecting lung cells but more efficient at infecting many upper respiratory tract cells.”
“This correlates with the pattern of disease observed in Omicron — while lower lung pathology is observed, upper airway disease is often more common,” he concluded.
In addition to causing less severe illness, the Omicron variant is also more transmissible. The animal and cell culture studies also suggest that Omicron may be more efficient at infecting the upper respiratory tract.
Studies conducted during the early stage of the pandemic show an association between levels of SARS-CoV-2 in the upper respiratory tract and increased transmission.
The faster replication of Omicron in the upper respiratory tract may thus explain its increased contagiousness.
“[These studies] give rise to an attractive speculation that the increased replication in upper airway tissues may contribute to increased transmissibility, potentially both by increasing the exhaled viral load and by decreasing the number of viral particles needed to infect, although, to my knowledge, this has not been demonstrated definitively,” Dr. Kasson explained.
The increased contagiousness of the Omicron variant may also be due to its ability to escape detection by antibodies.
Previous SARS-CoV-2 infections and immunization with COVID-19 vaccines lead to the production of antibodies that neutralize the virus. These neutralizing antibodies
The vaccines against COVID-19 have been designed to induce an immune reaction against the spike protein of the wild-type SARS-CoV-2 strain.
The presence of the mutations in the spike protein of the Omicron variant suggests that this variant may escape neutralization by antibodies.
A study led by researchers at the MRC-University of Glasgow Centre for Virus Research in the United Kingdom has shown that the Omicron variant can escape neutralization by antibodies in individuals immunized with the AstraZeneca COVID-19 vaccine. This could be another reason for the high transmissibility of the Omicron variant.
Although scientists need to carry out more research before we can draw solid conclusions, the characteristics of this new variant are slowly being revealed.
For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.